

Azure Health Technology Limited trading as VGI Health Technology appoints additional cGMP Manufacturer in US

Sydney New South Wales, 7 June 2021 – Azure Health Technology Limited trading as VGI Health Technology (the **Company** or **VTL**) is pleased to announce that an additional current Good Manufacturing Practice (cGMP) manufacturer has been appointed in the US.

VTL has executed a Manufacturing and Supply Agreement with Altipure LLC, a clinical partner of Muscle Feast, LLC in Ohio, USA, after the completion of a pilot manufacturing project which produced clinical study drugs for VTL's two Phase II clinical studies.

In this pilot manufacturing run which has recently been completed, 60,000 doses of active clinical study drug and 60,000 doses of placebo were manufactured and are expected to arrive in Australia in July 2021.

Of the 60,000 doses of active drug, half of the doses are IVB001 for VTL's Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) Phase II clinical study and the other half of the doses are IVB003 for VTL's Pancreatic Adenocarcinoma (Pancreatic Cancer) Phase II clinical study. Both IVB001 and IVB003 use the transmuscosal delivery platform for tocotrienols that is protected by VTL's granted patents in Australia, the US and other major markets such as the EU and Japan.

Concurrently with this pilot manufacturing run, Altipure also successfully validated and optimised the manufacturing process for the high throughput mass production of finished nutraceutical products, VTL's NE1-Elite® for Delayed Onset Muscle Soreness and muscle recovery and NE1-Heart®, for maintenance of heart health intended for sale in the US.

VTL's CEO and Managing Director, Dr Glenn Tong said "As we are now launching our nutraceutical products in the US, it is critically important that we build redundancy into our manufacturing capabilities so that if any issues arise with one manufacturer, our supply chain is not unduly interrupted. Altipure was introduced to us by our Scientific Advisory Board Member Dr Jordan Moon and through their manufacture of our clinical study drugs we have been very impressed with the efficiency of their operation and the professionalism of their staff. We now intend to use Altipure for the manufacture of both our clinical study drugs and finished nutraceutical products."

For more information please contact:

Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

Andrew Crook, Investor and Media Relations
Ph: +61 (0) 419 788 431

About Azure Health Technology Limited trading as VGI Health Technology

Azure Health Technology Limited trading as VGI Health Technology is an Australian public biotechnology company listed on the National Stock Exchange (NSX) with the ticker code NSX:VTL. VTL is developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

For more information see: <https://www.azureht.com.au>.

To track VTL on the NSX, see: <https://www.nsx.com.au/summary/VTL>